Nanotherapeutics for autoimmunity becomes mainstream
Clin Immunol
.
2015 Sep;160(1):1-2.
doi: 10.1016/j.clim.2015.07.006.
Epub 2015 Jul 11.
Authors
Nick Giannoukakis
1
,
Wilson S Meng
2
Affiliations
1
Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA, USA. Electronic address: ngiannou@wpahs.org.
2
Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA. Electronic address: meng@duq.edu.
PMID:
26172958
PMCID:
PMC4554816
DOI:
10.1016/j.clim.2015.07.006
No abstract available
Publication types
Editorial
MeSH terms
Autoimmune Diseases / therapy*
Autoimmunity
Drug Delivery Systems / methods*
Humans
Nanomedicine / methods*
Nanomedicine / trends*
Grants and funding
R15 AI081218/AI/NIAID NIH HHS/United States
R21 AI113000/AI/NIAID NIH HHS/United States